Market Overview

UPDATE: Stifel Nicolaus Initiates Johnson & Johnson at Hold; Fairly Valued

Share:
Related JNJ
S&P 500 Index Futures Trading Higher
A 'Gay Friendly' Portfolio Includes Apple, Microsoft & Disney...And It Beats The Market
Hospira bags French hospital group for Remicade biosimilar (Seeking Alpha)

Stifel Nicolaus initiated coverage on Johnson & Johnson (NYSE: JNJ) with a Hold rating.

Stifel Nicolaus noted, "We are initiating coverage of Johnson & Johnson (JNJ) with a Hold rating. We see JNJ as a core health care holding and total return vehicle in any environment for investors looking for safety and stability, particularly in these uncertain times. As JNJ continues to resolve recent issues and ex-FX sales growth reaccelerates modestly in each year over the next few years, JNJ shares should sustain its 12.6x forward P/E multiple, in line with the S&P 500."

Johnson & Johnson closed at $69.19 on Monday.

Latest Ratings for JNJ

DateFirmActionFromTo
May 2015JefferiesMaintainsHold
May 2015Deutsche BankMaintainsHold
Apr 2015Deutsche BankMaintainsHold

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (JNJ)

Around the Web, We're Loving...

Get Benzinga's Newsletters